Engineering TET2-deficient beta cells that resist autoimmune attack to create replacement cell therapies for type 1 diabetes.
Engineering HLA-DQ–specific CAR Tregs to selectively suppress anti-donor immune responses at sites of graft inflammation, this project seeks a more precise, durable alternative to broad immunosuppression in transplantation.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Identifying the autoantigens and T cell clonotypes driving immune attack in aplastic anemia to enable more precise diagnostics and targeted therapies.
Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.
Building a CHO cell surface display library of all human proteins to enable comprehensive, high-throughput autoantibody profiling across autoimmune diseases and vaccine responses.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Uncovering the mechanisms by which inflammasomes drive aberrant inflammation in humans to identify new therapeutic targets for autoinflammatory diseases and sepsis.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
